GVK Biosciences (GVK BIO), one of the leading contract research
organizations in Asia, has received full-accreditation from the
Association for the Assessment and Accreditation of Laboratory Animal
Care (AAALAC) International, a private, non-profit organization that
promotes the humane treatment of animals in science through voluntary
accreditation and assessment program, for its animal facilities.
The accreditation demonstrates GVK BIO’s commitment to high standards
of animal care. AAALAC commended the organization for promoting a
productive research environment that ensured high standards of humane
care and use of research animals.
“It is indeed a proud moment for us. The AAALAC certification
reiterates the fact that the team at GVK BIO is par excellent and
provides high-quality drug R&D services to its clients in a
regulatory-compliant environment,” said Dr JB Gupta, senior vice
president for collaborative research and
biology, GVK BIO.
The AAALAC certification will help in furthering GVK BIO’s growth in
the areas of pharmacology, ADME/DMPK, exploratory toxicology and animal
models. GVK BIO is the first organization in Hyderabad, and only the
sixth one in India to receive AAALAC certification. The endorsement is
a validation of GVK BIO’s abilities to deliver world-class solutions.
Lifesciences opens new CRO facility in Mumbai
Karmic Lifesciences, a Mumbai-based contract research
organization, has announced the opening of its new state-of-the-art
12,000 sq.ft. CRO facility at Airoli SEZ, Navi Mumbai. The new facility
has state-of-the-art facilities including fully-secure, biometrics
access, fire-proof, humidity-controlled central archival room, an
investigational product storage facility with up to -80º C ambient
temperatures, high-end rack servers, secure firewall and dedicated VPN
The inauguration was attended by over 200 guests including key industry
stakeholders from Indian Drug Manufacturers’ Association (IDMA) and
Organization of Pharmaceutical Producers of India (OPPI), as well as
several pharma companies, investigators and academicians. As one of
India’s fastest growing CROs, it was the next logical step for Karmic
to move to a much larger facility and Karmic views this event as a
major element in strengthening its positioning for global clients
including the US and Europe.
Nidhi Saxena, founder and CEO of Karmic Lifesciences, said, “The new
facility is a step towards getting to best-in-class and will help us
showcase ourselves as a technology-savvy CRO and ensure full-compliance
to US FDA and 21 CFR Part 11 standards. We will further be going in for
ISO 27001 (BS7799) certification shortly and will provide platinum
standard data security to our global clients. This move comes up with
several other initiatives we have embarked upon since we raised capital
earlier this year including strengthening the team, enhancing oncology
trial capabilities, developing a low-cost EDC solution, setting up a
preferred site network on a pan-India basis and setting up a
full-fledged sales operation in the US.”
Dr Shreekant Sapatnekar, medical director and COO, Karmic Lifesciences,
said “This is our moment of pride and takes us to a different league
from an operational and IT capability perspective. Apart from expanding
our overall operations, this move will give a strong fill-up to our
formidable clinical data management capability and establish us as one
of the CDM leaders from India.
gains 39.57 cr from new biz
Veeda Oncology, a full-service oncology CRO with facilities in North
America, Europe and India, has been awarded over
39.57 cr ($8.4 mn) of
new clinical research programs over the past 30 days.
The awarded work will be conducted in India, Europe and the US and will
include services for monitoring, data management and biostatistics,
medical monitoring, safety, site management and project management.
Matt Bowman, president and CEO, Veeda Oncology, said, “We are enjoying
our continued repeat business from our existing clients as well as from
Veeda Oncology is part of Veeda Group, the largest phase I CRO in India
also engaged in early clinical development and phase IIa clinical
research since 2005.